NCT02781480View on ClinicalTrials.gov

Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Leber Congenital Amaurosis
Interventions
BIOLOGICAL

AAV RPE65

Comparison of different dosages of AAV RPE65

Trial Locations (2)

48105

Kellogg Eye Centre, University of Michigan, Ann Arbor

EC1V 2PD

Moorfields Eye Hospital NHS Foundation Trust, London

All Listed Sponsors
lead

MeiraGTx UK II Ltd

INDUSTRY

NCT02781480 - Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA) | Biotech Hunter | Biotech Hunter